logologo
QuantliQuantli

Mink Therapeutics Inc

INKT

NASDAQ

Biotechnology

$11.27

USD

+0.27 (+2.45%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $54.80M

Volume 6.8K

Price (USD)
Price (USD)

About Mink Therapeutics Inc

The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2021-10-15.

CEO

Dr. Jennifer Buell

HQ

New York City, NEW YORK, US

Founded

2021

Employees

15

Key Metrics

1 metrics our research team weighs before forming a view on INKT.

Based on Quantli research · SEC filings · as of Q1 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Free Cash Flow (TTM)

$-6.32M

Financial Snapshot

Full Financials

Revenue

$0

YoY

Gross Margin

YoY

Net Income

$-12.47M

-28.1%

YoY

Operating Cash Flow

$-6.32M

+24.4%

YoY

Key Statistics

Open

$11.10

Previous Close

$11.00

Day Range

$10.95 - $11.50

52 Week Range

$8.48 - $18.17

Volume

6.8K

Average Volume (10 Days)

10.0K

Dividend Yield

Valuation Measurement

Market Cap

$54.80M

P/E Ratio (TTM)

Financial Highlights

Return on Assets

-120.2%

Return on Equity

98.3%

Revenue (TTM)

$0

Net Income (TTM)

$-12.47M

Diluted EPS (TTM)

-$2.83

Total Cash (MRQ)

$9.53M

Levered FCF (TTM)

$-6.32M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on INKT

Similar Stocks

BOLD

Boundless Bio Inc

$2.83

+2.0%

XLO

Xilio Therapeutics Inc

$9.17

+1.8%

CLNN

Clene Inc

$4.14

-1.2%

RNXT

RenovoRx Inc

$1.40

+11.1%

INMB

INmune Bio Inc

$2.17

+4.3%

ATYR

aTyr Pharma Inc

$0.5600

+1.1%

HRTX

Heron Therapeutics Inc

$0.3400

+0.7%

EXOZ

eXoZymes Inc

$5.82

-3.0%

MNOV

MediciNova Inc

$1.31

0.0%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 12

Est. EPS

Adjusted consensus estimate

-$0.64

Analyst Consensus

Buy

Based on 1 analyst ratings

Avg Target: $35.00

(+210.6% upside)

High: $35.00 · Low: $35.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings